Proteasome Treatment may Increase Risk of Cardiovascular Problems

Proteasome Treatment may Increase Risk of Cardiovascular Problems

New study carried out by Abramson Cancer Center of the University of Pennsylvania reports that carfilzomib drug can elevate risk of cardiovascular problems in patients suffering from multiple myeloma.

Findings of the study was published in JAMA Oncology journal in December 28, 2017. The proteasome inhibitor drug carfilzomib is used for treatment of multiple myeloma. Analysis of study shows that 18% of multiple myeloma patients receiving carfilzomib experienced cardiovascular adverse events (CVAE) such as hypertension, heart failure, heart attacks or arrhythmia.

More than eight percent of patients experience severe CVAEs more than twice as common as with other drugs for treating relapsed myeloma. According to estimates of American Cancer Society more than 30,200 people were suffering from MM in 2017. Standard treatments for treatment of these include chemotherapy and radiation and status of the patient can be improved with the use of proteasome inhibitors. FDA approved Carfilzomib as proteasome inhibitors, which has functions in breaking down and eliminate proteins inside a cell.

MM requires more proteasomes for survival of patients. The inhibitor drugs block the cells causing the cells to fill up with protein and die. “Like any cancer therapy, the concern with this approach is that it may have an effect on an otherwise healthy part of the body – in this case, the heart,” said the study’s lead author Adam J. Waxman, MD, a Hematology Oncology fellow in the Perelman School of Medicine at the University of Pennsylvania.

Results of the study found that 18.1% of patients taking carfilzomib experienced CVAE, with 8.2% of those cases being grade three or higher. For comparison, a similar review of bortezomib, another proteasome inhibitor found just 3.8% of patients experienced CVAE and only 2.3 percent were severe.

You may be interested

Single Cell Analysis Market : Global Sales, Ex-factory Price, Revenue, Gross Margin Analysis 2026
Healthcare
Healthcare

Single Cell Analysis Market : Global Sales, Ex-factory Price, Revenue, Gross Margin Analysis 2026

Mohit Joshi - October 16, 2018

The Single Cell Analysis Market is expected to have a highly positive outlook for the next eight years 2018-2026 according to a recently released Single Cell Analysis Market research report. The…

Audiology Devices Market Expansion to be Persistent During 2026
Healthcare
Healthcare

Audiology Devices Market Expansion to be Persistent During 2026

Mohit Joshi - October 16, 2018

The Audiology Devices Market is expected to have a highly positive outlook for the next eight years 2018-2026 according to a recently released Audiology Devices Market research report. The report has…

Ophthalmic Devices Market : Moving Towards a Brighter Future
Healthcare
Healthcare

Ophthalmic Devices Market : Moving Towards a Brighter Future

Mohit Joshi - October 16, 2018

The Ophthalmic Devices Market is expected to have a highly positive outlook for the next eight years 2018-2026 according to a recently released Ophthalmic Devices Market research report. The report has…

Most from this category